Article
Gilead profit misses Wall Street expectations as COVID drug sales decline
Rating:
0.0
Views:
40
Likes:
1
Library:
1
Gilead Sciences Inc on Thursday reported a lower-than-expected first-quarter profit as sales from COVID-19 antiviral Veklury declined more than anticipated, and its shares fell more than 2%.
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value